.jpg?format=webp&width=780)
The article discusses the importance of using patient-reported outcomes (PROs) in cardiovascular trials, regulatory and payer decisions, and patient care. Specifically, it highlights the need to develop PRO measures (PROMs) with the involvement of diverse patients, families, and caregivers, and to standardize the procedures for collecting, analyzing, and reporting PRO data. The article also emphasizes the importance of determining the "minimal clinically important difference" for different PROMs and populations. Overall, the article suggests that PROs are a critical part of patient care and drug development, and efforts should be made to ensure they are more widely employed.
Like
Save
Share